Different modes of data processing and statistical testing applied to the same set of pharmaco-eeg recordings: Effects on the evaluation of a selective and reversible mao a inhibitor (brofaromine)

Neuropsychobiology

Volumn 33, Issue 3, 1996, Pages 160-163

  Reimann, I W ^a   Jobert, M ^b   Gleiter, C H ^c   Turri, M ^d   Bieck, P R ^a   Herrmann, W M ^b  

^a Ciba Holding Deutschland GmbH   (Germany)

^b PAREXEL INTERNATIONAL   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d CIBA GEIGY LTD   (Switzerland)

Author keywords

Brofaromine; Descriptive data analysis; MAO A inhibitor; Pharmaco EEG; Spectral analysis

Indexed keywords

ANTIDEPRESSANT AGENT; BROFAROMINE; MONOAMINE OXIDASE A INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; PIPERIDINES;

EID: 0029884847     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119268     Document Type: Article

References (18)

1. Bcnte D: Vigilance and evaluation of psychotropic drug effects on EEG, Pharmacopsychiatry 1979;12:137-147.
2. Herrmann WM: Electroencephalography in Drug Research, Stuttgart, Fischer, 1982.
3. International Pharmaeo-EEG Group (IPEG), Committee on Standardization of Data Acquisition and Analysis in Pharmaco-EEG Investigations: Dummermuth G (Chairman), Ferber G, Herrmann WM, Hinrichs H, Künkel H: Recommendations for standardization of data acquisition and signal analysis in pharmaco-clectroenccphalography, Ncuropsychobiology 1987;17:213-218.
4. International Pharmacol-EEG Group (IPEG) Herrmann WM (Chairman) et al.; Recommendations for EEG and Evoked Potential Mapping, Neuropsychobiology 1989:227:170-176.
5. Collegium Internationale Psychiatriae Scala-rum (CIPS), Arbeitsgruppe ZNS Phase I: Nomenklatur Pharmako-EEG: Mitteilungen der Gesellschaft für Neuropsychologic, Z Neuro-psychol 1991:2:76-78.
6. Jobcrt M, Schulz H, Jähnig P: On the choice of recording duration in pharmaco-EEG studies, Ncuropsychobiology, in press.
7. 1), Arch Gerontol Geriatr 1988:7:93-110.
8. Fink M, Irwin P, Siborry P: EEG classification of a novel anorexigcnic: PR-F-36-CL; in Sudi-lovsky A, Gershon S, Beer B, (eds): Predictability in Psychopharmacology and Clinical Correlations, New York, Raven Press, 1975, pp 89-103.
9. Leonard JP, Ahlstich S, Lohmann H: Kognitive Vigilanzkontrollc im Pharmaco-EEG: Eine effektive, aufgabenbezogene Methode: in Ol-digs-Kerbcr J, Leonard J-P (eds): Pharmako-psychologic, Jena, Fischer, 1992, pp 265-284.
10. Biek P, Antonin KH, Jedrychowski M: Monoamine oxidase inhibition in healthy volunteers by CGPI1 305 A, a new specific inhibitor of MAO-A, Mod Probl Pharmacopsychiatry, Basel, Karger, 1983, vol 19, pp 53-62.
11. Schiwv W, Heath WR, Delini-Stula A: Therapeutic and sidc-elTcct profile of a selective and reversible MAO-A inhibitor, brofaromine, Results of dose-finding trials in depressed patients, J Neural Transm 1989;28(suppl) 33-44.
12. Moller HJ, Wendt G, Waldmeier P: Brofaromine - a selective, reversible and short-acting MAO-A inhibitor, Pharmacopsychiatry 1991; 24:50-54.
13. Jasper HH: The ten twenty electrode system of the International Federation, Elcctrocnccpha-logrClin Ncurophvsiol 1958:10:371-375.
14. Herrmann WM, Fichte K, Kubicki S: Definition von EEG-Frequenzbanderaufgrund siruk-turanalvtischcr Betrachtungen; in Kubicki S, Herrmann WM, Laudahn G (eds): Faktoren-analyse and Variablenbildung aus dem Electroencephalogramm, Stuttgart, Fischer, 1980.
15. Conover WJ, Iman RL: Rank transformations as a bridge between parametric and non-para-metric statistics, Am Statist 1981:35:124-129.
16. Abt K: Descriptive data analysis: A concept between confirmatory and exploratory data analysis, Methods Inf Med 1987;26:77-88.
17. J ah nig P, Jobcrt M: Methodological considerations for the evaluation of EEG mapping data: A practical example based on a placebo/diazepam crossover trial, Ncuropsychobiology 1995; 31:31-46.
18. Jobert M, Schulz H, Jahnig P: On the choice of recording duration in pharmaco-EEG studies, Neuropsychobiology 1995;32:106-114.